Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-08T02:12:34.315Z Has data issue: false hasContentIssue false
  • English
  • Français

Conflicts of Interest in Clinical Research: Addressing the Issue of Physician Remuneration

Published online by Cambridge University Press:  01 January 2021

Timothy Caulfield  and
Glenn Griener
Get access Rights & Permissions [Opens in a new window]

Extract

In the past few years, there have been a number of high profile incidents that have emphasized the issues associated with financial conflicts of interest. As a result, commentators and policy-makers throughout the world have been directing their attention to how financial conflicts should be addressed. Despite such activity, however, there are few policies that provide specific guidance addressing one of the most common forms of financial conflict-the provision of generous remuneration packages to clinical investigators.

In this column, we explore the conflict of interest issues that flow from the pharmaceutical industry paying community physicians to be investigators in clinical drug trials. In particular, we are interested in the challenges associated with the management of this complex issue by local research ethics boards. We suggest the need for more research on this topic and specific guidelines to empower these boards to address this growing concern. We recognize that this is one of many current conflict issues faced by policy-makers today.

Type
Currents in Contemporary Ethics
Information
Journal of Law, Medicine & Ethics , Volume 30 , Issue 2 , Summer 2002 , pp. 305 - 308
Copyright
Copyright © American Society of Law, Medicine and Ethics 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Eichenwald, K. Kolata, G., “Drug Trials Hide Conflict for Doctors,” New York Times, May 16, 1999, at A1.Google Scholar
Cech, T. Leonard, J., “Conflicts of Interests—Moving Beyond Disclosure,” Science, 291 (2001): 989; Pearlman, Heidi, “Top Medical Schools Seek End to Conflict of Interest Concerns,” Associated Press, February 8, 2001.CrossRefGoogle Scholar
Office for Human Research Protections, Financial Relationships in Clinical Trials: Issues for Institutions, Clinical Investigators, and IRBs to Consider When Dealing with Issues of Financial Interests and Human Subject Protection, Draft Interim Guidance (January 10, 2001), available at <http://ohrp.osophs.dhhs.gov/humansubjects/finreltn/finmain.htm>..>Google Scholar
Hailey, D., “Scientific Harassment by Pharmaceutical Companies: Time to Stop,” Canadian Medical Association Journal, 162 (2000): 212–13;. Horton, R., “Conflicts of Interest in Clinical Research: Opprobrium or Obsession?,” Lancet, 349 (1997): 1112.Google Scholar
Boyd, E., “Assessing Faculty Financial Relationships with Industry: A Case Study,” JAMA, 284 (2000): 2209–14.CrossRefGoogle Scholar
Goldner, J., “Dealing with Conflicts of Interest in Biomedical Research: IRB Oversight as the Next Best Solution to the Abolitionist Approach,” Journal of Law, Medicine & Ethics, 28 (2000): 379–404.Google Scholar
U.S. General Accounting Office, Report to Congressional Requesters, NIH Clinical Trials: Various Factors Affect Patient Participation, GAO/HEHS-99-182 (Washington, D.C.: General Accounting Office, 1999), available at <http://frwebgate.access.gpo.gov/cgi-bin/useftp.cgi?IPaddress=162.140.64.21&filename=he99182.pdf&directory=/diskb/wais/data/gao>..>Google Scholar
Bodenheimer, T., “Uneasy Alliance: Clinical Investigators and the Pharmaceutical Industry,” N. Engl. J. Med., 342 (2000): 1539–44.CrossRefGoogle Scholar
DeRenzo, E., “Coercion in the Recruitment and Retention of Human Research Subjects, Pharmaceutical Industry Payments to Physician-Investigators and the Moral Courage of the IRB,” IRB, 22 (2000): 1–5.CrossRefGoogle Scholar
Bodenheimer, , supra note 8.Google Scholar
Office of the Inspector General, Department of Health and Human Services, Recruiting Human Subjects: Pressures in Industry-Sponsored Clinical Research, OE1-01-97-00195 (Washington, D.C.: Department of Health and Human Services, June 2000), available at <http://oig.hhs.gov/oei/summaries/b459.pdf>..>Google Scholar
DeRenzo, , supra note 9.Google Scholar
DeAngelis, C., “Conflict of Interest and the Public Trust,” JAMA, 285 (2000): 2237–38.CrossRefGoogle Scholar
Office for Human Research Protections, supra note 3.Google Scholar
General Medical Council, Medical Research: The Role and Responsibilities of Doctors, Draft Guidance (March 2001), searchable at <http://www.gmc-uk.org/global_sections/search_frameset.htm>..>Google Scholar
Medical Research Council of Canada, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (August 1998), available at <http://www.nserc.ca/programs/ethics/english/ethics-e.pdf>. See also Australian National Health and Medical Research Council, National Statement on Ethical Conduct in Research Involving Humans (June 1999), available at <http://www.health.gov.au/nhmrc/publications/humans/preamble.htm>..+See+also+Australian+National+Health+and+Medical+Research+Council,+National+Statement+on+Ethical+Conduct+in+Research+Involving+Humans+(June+1999),+available+at+.>Google Scholar
Office for Human Research Protections, supra note 3.Google Scholar
Medical Research Council of Canada, supra note 16.Google Scholar
Canadian Medical Association, “Physicians and the Pharmaceutical Industry,” Canadian Medical Association Journal, 164 (2001): 1339–41.Google Scholar
DeRenzo, , supra note 9.Google Scholar
Cech, Leonard, , supra note 2.Google Scholar
Caulfield, T., “Globalization, Conflicts of Interest and Clinical Research: An Overview of Trends and Issues,” Widener Law Symposium Journal, 8 (2001): 31–45.Google Scholar
McDonald, M.et al., The Governance of Health Research Involving Human Subjects (May 2000). Report commissioned by the Law Commission of Canada, available at <http://www.lcc.gc.ca/en/themes/gr/hrish/macdonald/macdonald.pdf>..>Google Scholar
Friedberg, M.et al., “Evaluation of Conflict of Interest in Economic Analysis of New Drug Trials in Oncology,” JAMA, 282 (1999): 1453–57.CrossRefGoogle Scholar
DeRenzo, , supra note 9; Goldner, , supra note 6.Google Scholar
U.S. General Accounting Office, supra note 7.Google Scholar